The Associations Between IL-18 Serum Levels and the Prevalence of Metabolic Syndrome in Polish Men Over the Age of 40 According to Other Selected Inflammatory Indices and Androgens: Comparison of NCEP with IDF Criteria

Abstract

Background: The frequency of MS increases with age and augments the cardiovascular risk. The criteria for distinguishing MS constantly evolve. The aim of the study was to estimate the reciprocal links between low-grade inflammation, selected serum androgens and prevalence of MS, according to NCEP and IDF criteria, in Polish men over the age of 40.

Materials and Methods: A sample of 160 men was randomly selected from men at the age of 40, 50, 60 and 70, residing in the rural south-western region of Poland. IL-18 and CRP, transferrin, α₁-antichymotrypsin, dehydroepiandrosterone and its sulfate as well as free-testosterone levels were evaluated.

Results: The prevalence of MS was 37.5% using NCEP criteria and 46.25% employing IDF indices. Patients with MS diagnosed according to criteria proposed by NCEP and IDF exhibit a similar hormonal and immunological profile. Age was positively correlated with CRP (r=0.231; p<0.0005), and α₁-ACT (r=0.191 p<0.05) and negatively with transferrin (r=−0.27; p<0.001), but not with IL-18 plasma levels. Both adrenal androgens were negatively correlated with age: DHEA r=−0.489; p<0.001 and DHEAS: r=−0.553; p<0.001 respectively, in contrast to free-testosterone. People suffering from MS have shown a significantly higher level of IL-18 and CRP. The number of MS components identified (according to NCEP) is positively correlated only with IL-18 serum levels (r=0.226; p=0.043).

Conclusions: Inflammatory parameters were better than a deficit of androgens in identifying men suffering from MS. However, the best correlation with the number of MS components was revealed by IL-18 plasma levels.

IL-18 - metabolic syndrome - androgen deficiency - ageing men

References

• 1 Alberti KG, Eckel RH, Grundy SM. et al . Harmonizing the MS: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association, World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.  Circulation. 2009;  120 1640-1645
• 2 Berneis K, Rizzo M, Evans J. et al . Interleukin-18 levels are associated with low-density lipoprotein size.  Eur J Clin Invest. 2010;  40 54-55
• 3 Blankenberg S, Luc G, Ducimetiere P. et al . Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME).  Circulation. 2003;  108 2453-2459
• 4 Bruun JM, Stallknecht B, Helge JW. et al . Interleukin-18 in plasma and adipose tissue: effect of obesity, insulin resistance, and weight loss.  Eur J Endocrinol. 2007;  157 465-471
• 5 Brown CD, Higgins M, Donato KA. et al . BMI and prevalence of hypertension and dyslipidemia.  Obesity Res. 2000;  8 605-619
• 6 Chae C, Lee R, Rifai N. et al . Blood pressure and inflammation in apparently healthy men.  Hypertension. 2001;  38 399-403
• 7 Chapman CM, McQuillan BM, Beilby JP. et al . Interleukin-18 levels are not associated with subclinical carotid atherosclerosis in a community population. The Perth Carotid Ultrasound Disease assessment Study (CUDAS).  Atherosclerosis. 2006;  189 414-419
• 8 Chen YC, Chang HH, Wen CJ. et al . Elevated serum dehydroepiandrosterone sulphate level correlates with increased risk for metabolic syndrome in the elderly men.  Eur J Clin Invest. 2010;  40 22-225
• 9 Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory.  Semin Nephrol. 2007;  27 98-114
• 10 Esposito K, Pontillo A, Ciotola M. et al . Weight loss reduces IL-18 levels in obese women.  J Clin Endocrinol Metab. 2002;  87 3864-3866
• 11 Fain JN, Madan AK, Hiler ML. et al . Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans.  Endocrinology. 2004;  145 2273-2282
• 12 Grundy SM, Brewer Jr HB, Cleeman JI. et al . Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.  Arterioscler Thromb Vasc Biol. 2004;  24 13-18
• 13 Hemingway H, Shipley M, Mullen MJ. et al . Social and physiological influences on inflammatory markers and vascular function in civil servants (the Whitehall II study).  Am J Cardiol. 2003;  92 984-987
• 14 Herder C, Baumert J, Kolb H. et al . Circulating levels of interleukin-18 independent of body fat and fat-free mass: results from the MONICA/KORA study.  Diabetes Care. 2006;  29 174-175
• 15 Hung J, Knuiman MW, Divitini ML. et al . C-reactive protein and interleukin-18 levels in relation to coronary heart disease: prospective cohort study from Busselton Western Australia.  Heart Lung Circ. 2008;  17 90-95
• 16 Hung J, McQuillan BM, Chapman CML. et al . Elevated interleukin-18 levels are associated with metabolic syndrome independent of obesity and insulin resistance.  Arterioscler Thromb Vasc Biol. 2005;  25 1268-1273
• 17 Janssen I, Katzmarzyk PT, Ross R. BMI, waist circumference, and health risk: evidence in support of current National Institutes of health guidelines.  Arch Intern Med. 2002;  162 2074-2079
• 18 Kahn R, Buse J, Ferranini E. et al . The metabolic syndrome; time for a critical appraisal. Joint statement from the American Diabetes Association from the study of Diabetes.  Diabetologia. 2005;  48 1684-1699
• 19 Kaptoge S, Di Angelantonio E, Lowe G. et al . Emerging Risk Factor Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.  Lancet. 2010;  375 132-140
• 20 Koenig W, Khuseyinova N, Baumert J. et al . Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women:results from the MONICA/KORA Augsburg case-cohort study, 1984–2002.  Arterioscler Thromb Vasc Biol. 2006;  26 275-2751
• 21 Krogh-Madsen R, Plomgaard P, Moller K. et al . Influence of TNF-α and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans.  Am J Physiol Endocrinol Metab. 2006;  291 E 108-E 114
• 22 Lechleitner M. Obesity and the metabolic syndrome in the elderly – a mini review.  Gerontology. 2008;  54 253-259
• 23 Mamcarz A, Podolec P, Kopeć G. et al . Polish forum for prevention guidelines on MS.  Kardiol Pol. 2010;  68 121-124
• 24 Miles EA, Rees D, Banerjee T. et al . Age-related increases in circulatineg inflammatory markers in men are independent of BMI, blood pressure and blood lipid concentrations.  Atherosclerosis. 2008;  196 298-305
• 25 Nakamura K, Okamura H, Nagata K. et al . Purification of a factor which provides a costimulatory signal for gamma interferon production.  Infect Immun. 1993;  61 64-70
• 26 Nakanishi K, Yoshimoto T, Tsutsui H. et al . Interleukin-18 regulates both Th1 and Th2 responses.  Annu Rev Immunol. 2001;  19 423-474
• 27 Novick D, Kim SH, Fantuzzi G. et al . Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response.  Immunity. 1999;  10 127-136
• 28 Olusi SO, Al-Awadhi A, Abraham M. Relations of serum interleukin18 levels to serum lipid and glucose concentrations in an apparently healthy adult population.  Horm Res. 2003;  60 29-33
• 29 Phillips AC, Carroll D, Gale CR. et al . Cortisol, DHEAS, their ratio and the metabolic syndrome: evidence from the Vietnam Experience Study.  Eur J Endocrinol. 2010;  162 919-923
• 30 Ruotsalainen E, Stancakova A, Vauhkonen I. et al . Changes In cytokine levels during acute hyperinsulinemia in offspring of type 2 diabetic subjects.  Atherosclerosis. 2010;  210 536-541
• 31 Skurk T, Kolb H, Muller-Scholze S. et al . The proatherogenic cytokine interleukin-18 is secreted by human adipocytes.  Eur J Endocrinol. 2005;  152 863-868
• 32 Steinberg D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime.  Nat Med. 2002;  8 1211-1217
• 33 Stenholm S, Koster A, Alley DE. et al . Adipocytokines and the metabolic syndrome among older persons with and without obesity – the InCHIANTI Study.  Clin Endocrinol (Oxf). 2009;  73 55-65
• 34 Sugama S, Conti B. Interleukin-18 and stress.  Brain Res Rev. 2008;  58 85-95
• 35 Tannenbaumm C, Barrett-Connor E, Laughlin GA. et al . A longitudinal study of dehydroepiandrosterone sulphate (DHEAS) change in older men and women: the Rancho Bernardo Study.  Eur J Endocrinol. 2004;  151 717-725
• 36 The IDF consensus worldwide definition of the metabolic syndrome. . Berlin 14th April 2005;  http://[e-mail] http://www.idf.org
• 37 Thorand B, Kolb H, Baumert J. et al . Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984–2002.  Diabetes. 2005;  54 2932-2938
• 38 Troseid M, Seljeflot I, Hjerkinn EM. et al . Interleukin-18 is a strong predictor of cardiovascular events in elderly men with metabolic syndrome: synergistic effect of inflammation and hyperglycemia.  Diabetes Care. 2009;  32 486-492
• 39 Welsh P, Woodward M, Rumley A. et al . Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study.  Br J Haematol. 2008;  141 852-861
• 40 Zirlik A, Abdullah SM, Gerdes N. et al . Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis. Results from the Dallas Heart Study.  Arterioscler Thromb Vasc Biol. 2007;  27 2043-2049

Correspondence